BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28489574)

  • 1. Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment.
    Wang T; Chen S; Wang S; Shi L; Wang C; Zhang J; Gao Y; Li G; Qi Y; An X; Chen L
    Oncotarget; 2017 Jun; 8(25):40713-40723. PubMed ID: 28489574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro.
    Chiang KC; Sun CC; Chen MH; Huang CY; Hsu JT; Yeh TS; Chen LW; Kuo SF; Juang HH; Takano M; Kittaka A; Chen TC; Yeh CN; Pang JH
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):26-34. PubMed ID: 26385607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemokinins modulate endothelium function and promote angiogenesis through neurokinin-1 receptor.
    Song H; Yin W; Zeng Q; Jia H; Lin L; Liu X; Mu L; Wang R
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1410-21. PubMed ID: 22554585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel neurokinin 3 receptor (NK3R) selective agonists with resistance to proteolytic degradation.
    Misu R; Oishi S; Yamada A; Yamamura T; Matsuda F; Yamamoto K; Noguchi T; Ohno H; Okamura H; Ohkura S; Fujii N
    J Med Chem; 2014 Oct; 57(20):8646-51. PubMed ID: 25247671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursolic acid-loaded chitosan nanoparticles induce potent anti-angiogenesis in tumor.
    Jin H; Pi J; Yang F; Wu C; Cheng X; Bai H; Huang D; Jiang J; Cai J; Chen ZW
    Appl Microbiol Biotechnol; 2016 Aug; 100(15):6643-6652. PubMed ID: 26883344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
    Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
    Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of tachykinin peptides for the development of novel neurokinin-3 receptor selective agonists.
    Misu R; Noguchi T; Ohno H; Oishi S; Fujii N
    Bioorg Med Chem; 2013 Apr; 21(8):2413-2417. PubMed ID: 23473945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Davallia bilabiata exhibits anti-angiogenic effect with modified MMP-2/TIMP-2 secretion and inhibited VEGF ligand/receptors expression in vascular endothelial cells.
    Liu CT; Bi KW; Huang CC; Wu HT; Ho HY; S Pang JH; Huang ST
    J Ethnopharmacol; 2017 Jan; 196():213-224. PubMed ID: 27993633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
    Chuang CH; Liu CH; Lu TJ; Hu ML
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety.
    Nkembo AT; Ntantie E; Salako OO; Amissah F; Poku RA; Latinwo LM; Lamango NS
    Oncotarget; 2016 Oct; 7(42):68194-68205. PubMed ID: 27626690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis.
    Pal S; Wu J; Murray JK; Gellman SH; Wozniak MA; Keely PJ; Boyer ME; Gomez TM; Hasso SM; Fallon JF; Bresnick EH
    J Cell Biol; 2006 Sep; 174(7):1047-58. PubMed ID: 17000881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of 2,4-disubstituted quinazoline derivatives with potent anti-angiogenesis activities.
    Yu G; Li Z; Tang L; Xiong Q
    Molecules; 2014 Jun; 19(7):8916-32. PubMed ID: 24972275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
    Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.